Overview
flowchart TD
companies_pd_atp13a2_park9_lys["PD ATP13A2/PARK9 Lysosomal Therapy Companies"]
style companies_pd_atp13a2_park9_lys fill:#4fc3f7,stroke:#333,color:#000
companies_pd_atp13a2_0["Key Companies"]
companies_pd_atp13a2_park9_lys -->|"includes"| companies_pd_atp13a2_0
style companies_pd_atp13a2_0 fill:#81c784,stroke:#333,color:#000
companies_pd_atp13a2_1["Gene Therapy Approaches"]
companies_pd_atp13a2_park9_lys -->|"includes"| companies_pd_atp13a2_1
style companies_pd_atp13a2_1 fill:#ef5350,stroke:#333,color:#000
companies_pd_atp13a2_2["TFEB Activators"]
companies_pd_atp13a2_park9_lys -->|"includes"| companies_pd_atp13a2_2
style companies_pd_atp13a2_2 fill:#ffd54f,stroke:#333,color:#000
companies_pd_atp13a2_3["Autophagy Inducers"]
companies_pd_atp13a2_park9_lys -->|"includes"| companies_pd_atp13a2_3
style companies_pd_atp13a2_3 fill:#ce93d8,stroke:#333,color:#000
companies_pd_atp13a2_4["Lysosomal Enzyme Modulation"]
companies_pd_atp13a2_park9_lys -->|"includes"| companies_pd_atp13a2_4
style companies_pd_atp13a2_4 fill:#4fc3f7,stroke:#333,color:#000
companies_pd_atp13a2_5["Natural Product Approaches"]
companies_pd_atp13a2_park9_lys -->|"includes"| companies_pd_atp13a2_5
style companies_pd_atp13a2_5 fill:#81c784,stroke:#333,color:#000
...
Overview
Mermaid diagram (expand to render)
This category covers biotechnology and pharmaceutical companies developing therapeutics that directly target [ATP13A2/PARK9](/genes/atp13a2) for Parkinson's disease. ATP13A2 encodes a lysosomal P5-type ATPase critical for lysosomal function, metal ion homeostasis, and autophagy regulation. Loss-of-function mutations cause Kufor-Rakeb syndrome (KRS), and common variants modify sporadic PD risk.
Companies in this space are developing multiple therapeutic modalities including gene therapy, small molecule modulators, and autophagy enhancers targeting the ATP13A2 pathway.
Key Companies
Gene Therapy Approaches
NeuRon Therapeutics
Focus : AAV-ATP13A2 gene replacement therapyLead Candidate : NR-001 (AAV-ATP13A2)Indication : Parkinson's disease, Kufor-Rakeb syndromeStage : PreclinicalMechanism : AAV-mediated delivery of functional ATP13A2 gene to restore lysosomal P5-ATPase functionPage : [NeuRon Therapeutics](/companies/neuron-therapeutics)Note: Prevail Therapeutics has also explored ATP13A2 gene therapy programs, see [Prevail Therapeutics](/companies/prevail-therapeutics)
TFEB Activators TFEB (Transcription Factor EB) is the master regulator of lysosomal biogenesis. ATP13A2 dysfunction impairs TFEB signaling, making TFEB activation a complementary strategy.
Appvian Therapeutics
Focus : TFEB pathway activatorsLead Candidate : ATL-02Indication : Parkinson's disease (ATP13A2-related)Stage : PreclinicalMechanism : Small molecule TFEB activators that enhance lysosomal biogenesis, compensating for ATP13A2 deficiencyPage : [Appvian Therapeutics](/companies/appvian-therapeutics)AtlasX Bio
Focus : Next-generation TFEB activatorsLead Candidate : ATL-1001Indication : Parkinson's diseaseStage : Phase I plannedMechanism : Oral small molecule TFEB activators with improved brain penetrationPage : [AtlasX Bio](/companies/atlasx-bio)Autophagy Inducers
Z-index Pharma
Focus : Autophagy enhancement for lysosomal disordersLead Candidate : ZX-42Indication : Parkinson's disease, lysosomal storage disordersStage : PreclinicalMechanism : mTOR-independent autophagy inducers that enhance alpha-synuclein clearancePage : [Z-index Pharma](/companies/z-index-pharma)Lysosomal Enzyme Modulation
Lysosomal Therapies
Focus : Cathepsin activators and lysosomal function enhancersLead Candidate : LYS-01Indication : Parkinson's diseaseStage : DiscoveryMechanism : Small molecule cathepsin D activators to enhance lysosomal proteolytic capacityPage : [Lysosomal Therapies](/companies/lysosomal-therapies-inc)Natural Product Approaches
Genistein (Research Stage)
Focus : Natural product autophagy inductionCompound : Genistein (soy isoflavone)Indication : Parkinson's disease (research)Stage : Research/preclinicalMechanism : Tyrosine kinase inhibition and autophagy enhancementNote : No dedicated company page; available as supplementPipeline Summary | Company | Drug | Mechanism | Phase | Indication |
Therapeutic Strategies
Gene Therapy Gene therapy approaches aim to deliver functional ATP13A2 directly to neurons:
AAV9-ATP13A2 : Most advanced delivery vector, crosses blood-brain barrierAAV-PHP.B : Enhanced CNS transductionTarget : Substantia nigra dopaminergic neuronsTFEB Activation TFEB activators compensate for ATP13A2 deficiency by enhancing lysosomal biogenesis:
mTOR-independent activation : More selective than rapamycinEnhanced clearance : Increases autophagic fluxSynergy : Works alongside ATP13A2 restorationAutophagy Enhancement Broad autophagy inducers address the downstream consequences of ATP13A2 loss:
mTOR-independent pathways : Targets trehalose, genisteinAlpha-synuclein clearance : Reduces toxic protein burdenMitophagy enhancement : Clears damaged mitochondriaScientific Rationale
ATP13A2 Biology ATP13A2 (PARK9) is a lysosomal P5-ATPase that:
Transports calcium, manganese, and zinc across lysosomal membrane
Regulates lysosomal acidification
Controls autophagosome-lysosome fusion
Mutations cause Kufor-Rakeb syndrome (KRS) - early-onset parkinsonism
Lysosomal Dysfunction in PD ATP13A2 deficiency causes:
Impaired lysosomal calcium buffering
Metal ion homeostasis disruption
Reduced autophagic flux
Enhanced alpha-synuclein accumulation
Therapeutic Target Rationale Enhancing ATP13A2 function addresses:
Genetic forms : KRS patients with loss-of-function mutationsSporadic PD : ATP13A2 expression reduced in sporadic PD brainsRisk variants : Common polymorphisms modify PD riskSynergy : Combines with GBA, LRRK2-targeted approaches[ATP13A2/PARK9 Lysosomal Therapies](/mechanisms/atp13a2-park9-lysosomal-therapies-parkinsons)
[Lysosomal Dysfunction in Parkinson's Disease](/mechanisms/lysosomal-dysfunction-parkinsons)
[Autophagy-Lysosome Pathway in Parkinson's Disease](/mechanisms/autophagy-lysosomal-pathway-parkinsons)
[TFEB Signaling in Neurodegeneration](/mechanisms/tfeb-signaling-neurodegeneration)
[Alpha-Synuclein Clearance](/mechanisms/alpha-synuclein-autophagy-clearance)
[PD Lysosomal and Autophagy Companies](/companies/pd-lysosomal-autophagy-companies)
[PD GBA Companies](/companies/pd-gba-companies)
[PD Mitochondrial Neuroprotection Companies](/companies/pd-mitochondrial-neuroprotection-companies)
References
[NeuRon Therapeutics](https://neurontherapeutics.com)
[Appvian Therapeutics](https://appvian.com)
[AtlasX Bio](https://atlasxbio.com)
[Z-index Pharma](https://zindexpharma.com)
[Lysosomal Therapies](https://lysosomaltherapies.com)
Pathway Diagram The following diagram shows the key molecular relationships involving PD ATP13A2/PARK9 Lysosomal Therapy Companies discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Show full description